These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29885478)

  • 21. Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
    Mehlman C; Chaabane N; Lacave R; Kerrou K; Ruppert AM; Cadranel J; Fallet V
    J Thorac Oncol; 2019 May; 14(5):e95-e96. PubMed ID: 31027750
    [No Abstract]   [Full Text] [Related]  

  • 22. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
    Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
    Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
    Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
    Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
    Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
    J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Millett RL; Elkon JM; Tabbara IA
    Anticancer Res; 2018 Sep; 38(9):4969-4975. PubMed ID: 30194140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
    J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
    Doménech M; Jové M; Aso S; Marín M; Nadal E
    Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brigatinib Approved, but Treatment Role Uncertain.
    Cancer Discov; 2017 Jul; 7(7):OF3. PubMed ID: 28536155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of systemic brigatinib therapy in tumour recurrence of choroid metastasis from non-small cell lung carcinoma.
    Kim RS; Nguyen MK; Card KR; Shields CL
    Can J Ophthalmol; 2024 Aug; 59(4):e397-e399. PubMed ID: 37236265
    [No Abstract]   [Full Text] [Related]  

  • 32. [Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer].
    Lu Z; Cai J; Zeng Z; Liu A
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):710-718. PubMed ID: 32758347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
    Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
    Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
    J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
    Tsui DCC; Kavanagh BD; Honce JM; Rossi C; Patil T; Camidge DR
    Clin Lung Cancer; 2022 Jan; 23(1):e5-e8. PubMed ID: 34246540
    [No Abstract]   [Full Text] [Related]  

  • 37. Phototoxic reaction to brigatinib - a new photosensitizing drug.
    Morgado F; Calvão J; Barata F; Gonçalo M
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e491-e492. PubMed ID: 31325397
    [No Abstract]   [Full Text] [Related]  

  • 38. Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?
    Tabbò F; D'Aveni A; Tota D; Pignataro D; Bironzo P; Carnio S; Cappia S; Cortese G; Righi L; Novello S
    J Thorac Oncol; 2019 Feb; 14(2):e38-e40. PubMed ID: 30683298
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful treatment with ceritinib after crizotinib induced hepatitis.
    Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
    Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer.
    Sakuma I; Nagano H; Yoshino I; Yokote K; Tanaka T
    Intern Med; 2019 Mar; 58(6):817-820. PubMed ID: 30449809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.